Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

1.0K
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
1.0K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.7K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.7K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

844
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
844
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.8K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.8K
Nursing Interventions I: Taxonomy of Nursing Interventions01:03

Nursing Interventions I: Taxonomy of Nursing Interventions

3.9K
Nursing interventions are chosen as part of the planning process to achieve patient outcomes. Once nursing diagnoses are determined, the goals and outcomes are specified, then the nursing interventions are selected and individualized according to the patient's situation.
A nursing intervention is a treatment or action based on scientific concepts and knowledge from the nursing, behavioral, and physical sciences. Identifying and prioritizing nursing interventions based on the desired outcome...
3.9K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

2.5K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Novel Host-Based Immunotherapy for the Suppression of HBV and HCV Replication: Heat-Killed <i>Caulobacter crescentus</i> (HKCC).

Cells·2026
Same author

Successful Management of <i>Achromobacter</i>-Associated Periprosthetic Joint Infections After Total Knee Arthroplasty: A Case Series of Ten Knees in Six Patients.

Arthroplasty today·2026
Same author

Herbal toothpaste craze: A marketing triumph or a public health concern.

Bioinformation·2026
Same author

Host-directed broad-spectrum immunotherapeutic strategy for respiratory infections: Heat-killed Caulobacter crescentus (HKCC) as an innate-immune based biotherapeutic/postbiotic.

PLoS pathogens·2026
Same author

Evaluating periapical and periodontal health in root canal treated teeth using various obturation methods.

Bioinformation·2025
Same author

Mixed lipopeptide-based mucosal vaccine elicits a long-term bone marrow memory response that is potentially cross-reactive against a broad-spectrum of coronaviruses in mice.

Frontiers in immunology·2025

Related Experiment Video

Updated: May 5, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.1K

Chemotherapeutic interventions against tuberculosis.

Neeraj Shakya1, Gaurav Garg, Babita Agrawal

  • 1Department of Laboratory Medicine and Pathology, 728-Heritage Medical Research Center, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2S2, Canada. rkumar@ualberta.ca.

Pharmaceuticals (Basel, Switzerland)
|November 28, 2013
PubMed
Summary

Tuberculosis treatment faces challenges from drug resistance and side effects. This review explores existing and novel anti-tuberculosis agents to combat these issues.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.1K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.4K

Related Experiment Videos

Last Updated: May 5, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.1K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.1K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.4K

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Tuberculosis (TB) remains a leading global infectious cause of death.
  • Conventional antimycobacterial drugs are losing efficacy due to multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB).
  • Current TB treatments are associated with significant side effects, drug interactions, and prolonged administration.

Purpose of the Study:

  • To review current tuberculosis chemotherapeutics.
  • To highlight the therapeutic potential of novel anti-tuberculosis agents in development.
  • To address the urgent need for new treatments against resistant TB strains.

Main Methods:

  • Literature review of existing and emerging anti-tuberculosis compounds.
  • Analysis of drug resistance patterns and treatment challenges.
  • Evaluation of novel therapeutic strategies for tuberculosis management.

Main Results:

  • Conventional drugs face limitations due to widespread drug resistance (MDR-TB, XDR-TB).
  • Emerging molecular families show promise for treating resistant tuberculosis.
  • Several new anti-TB agents are in various stages of preclinical and clinical development.

Conclusions:

  • There is a critical need for novel anti-tuberculosis drugs.
  • Emerging compounds offer potential solutions to combat drug-resistant TB.
  • Continued research and development are essential for effective tuberculosis treatment.